These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38126033)

  • 1. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
    Reid P; Sandigursky S; Song J; Lopez-Olivo MA; Safa H; Cytryn S; Efuni E; Buni M; Pavlick A; Krogsgaard M; Abu-Shawer O; Altan M; Weber JS; Rahma OE; Suarez-Almazor ME; Diab A; Abdel-Wahab N
    Oncoimmunology; 2023; 12(1):2261264. PubMed ID: 38126033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
    Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
    Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
    Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
    Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data.
    Tully KH; Cone EB; Cole AP; Sun M; Chen X; Marchese M; Roghmann F; Kilbridge KL; Trinh QD
    Am J Clin Oncol; 2021 Aug; 44(8):413-418. PubMed ID: 34081033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
    van der Kooij MK; Suijkerbuijk KPM; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Breeschoten J; van den Eertwegh AJM; de Groot JWB; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Dekkers OM; Kapiteijn E
    Ann Intern Med; 2021 May; 174(5):641-648. PubMed ID: 33587686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.
    Kumar R; Chan A; Bandikatla S; Ranjan S; Ngo P
    Curr Probl Cancer; 2022 Aug; 46(4):100864. PubMed ID: 35671576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
    Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
    Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
    Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
    Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
    Plaçais L; Dalle S; Dereure O; Trabelsi S; Dalac S; Legoupil D; Montaudié H; Arnault JP; De Quatrebarbes J; Saiag P; Brunet-Possenti F; Lesimple T; Maubec E; Aubin F; Granel-Brocard F; Grob JJ; Stoebner PE; Allayous C; Oriano B; Dutriaux C; Mortier L; Lebbe C
    Ann Rheum Dis; 2022 Oct; 81(10):1445-1452. PubMed ID: 35788496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
    Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
    Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors.
    Gulati N; Celen A; Johannet P; Mehnert JM; Weber J; Krogsgaard M; Osman I; Zhong J
    Cancer Med; 2021 Nov; 10(21):7457-7465. PubMed ID: 34647433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis.
    Cai Q; Huo GW; Zhu FY; Yue P; Yuan DQ; Chen P
    Hum Vaccin Immunother; 2022 Dec; 18(7):2145102. PubMed ID: 36471629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.